Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

Rheumatology (United Kingdom)

Volumn 55, Issue 8, 2016, Pages 1499-1506

  Kullenberg, Torbjörn ^a   Löfqvist, Malin ^a   Leinonen, Mika ^a,b   Goldbach Mansky, Raphaela ^c   Olivecrona, Hans ^a  

^a Research and Development   (Sweden)

^b Statistics   (Sweden)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Adverse event (AE); Anakinra; Clinical trial; Cryopyrin associated periodic syndromes (CAPS); Headache; Infections; Injection site reactions (ISR); Neonatal onset multisystem inflammatory disease (NOMID); Safety

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ADULT; APPLICATION SITE RASH; ARTHRALGIA; ARTICLE; BACKACHE; BACTERIAL ARTHRITIS; CELLULITIS; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CONVULSION; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; ECZEMA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HEADACHE; HEART CATHETERIZATION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIMB PAIN; LONG TERM CARE; LYMPHADENITIS; MACROPHAGE ACTIVATION SYNDROME; MAINTENANCE DRUG DOSE; MALE; MENINGITIS; NAUSEA; NECK PAIN; NOSE OBSTRUCTION; OCULAR HYPEREMIA; OPEN STUDY; OROPHARYNX PAIN; OTITIS MEDIA; PNEUMONIA; POST LUMBAR PUNCTURE SYNDROME; POSTOPERATIVE INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RHINOPHARYNGITIS; SCHOOL CHILD; SINUSITIS; SLEEP DISORDER; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VIRUS INFECTION; VOMITING; WOUND INFECTION; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DOSE RESPONSE; DRUG ADMINISTRATION; HEADACHE AND FACIAL PAIN; MIDDLE AGED; PATIENT SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRALGIA; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROENTERITIS; HEADACHE DISORDERS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PATIENT SAFETY; PNEUMONIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988583499     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew208     Document Type: Article

References (18)

1. Hoffman HM. Rilonacept for the treatment of cryopyrinassociated periodic syndromes (CAPS). Expert Opin Biol Ther 2009;9:519-31.
2. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 2011;63:314-24.
3. Touitou I, Sarkisian T, Medlej-Hashim M et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-12.
4. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92.
5. Prieur AM, Griscelli C, Lampert F et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68.
6. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006;126:659-62.
7. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4.
8. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52.
9. Sibley CH, Plass N, Snow J et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three-and five-year outcomes. Arthritis Rheum 2012;64:2375-86.
10. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
11. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
12. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8.
13. den Broeder AA, de Jong E, Franssen MJ et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2.
14. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009;CD005121.
15. Kaiser C, Knight A, Nordstrom D et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012;32:295-9.
16. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118-25.
17. Aubert P, Suarez-Farinas M, Mitsui H et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. PloS One 2012;7:e49408.
18. Graham NM. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990;12:149-78.